Gumus, M. Et Al. 2021. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15 .

Gumus, M., Chen, C., Ivanescu, C., Kilickap, S., Bondarenko, I., Ozguroglu, M., ... Gogishvili, M.(2021). Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

Gumus, Mahmut Et Al. "Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Gumus, Mahmut Et Al. "Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Gumus, M. Et Al. (2021) . "Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

@article{article, author={Mahmut Gumus Et Al. }, title={Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}